Free Trial
NASDAQ:CRBP

Corbus Pharmaceuticals Q4 2024 Earnings Report

Corbus Pharmaceuticals logo
$7.31 -0.05 (-0.68%)
As of 09:55 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Corbus Pharmaceuticals EPS Results

Actual EPS
-$0.78
Consensus EPS
-$1.02
Beat/Miss
Beat by +$0.24
One Year Ago EPS
N/A

Corbus Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Corbus Pharmaceuticals Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Tuesday, March 11, 2025
Conference Call Time
8:30AM ET

Upcoming Earnings

Corbus Pharmaceuticals' Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Corbus Pharmaceuticals Earnings Headlines

Elon’s 2025 Silver Crisis (What It Means for You)
Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless production of electric vehicles and solar technology is driving demand for the precious metal to unprecedented levels. Silver—critical for EV batteries, solar panels, and advanced electronics—is now at the center of a supply crisis.
See More Corbus Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Corbus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corbus Pharmaceuticals and other key companies, straight to your email.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals (NASDAQ:CRBP), a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

View Corbus Pharmaceuticals Profile

More Earnings Resources from MarketBeat